VENT-02

· Ventus Therapeutics U.S., Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VENT-02, covering 2025-10-29 to 2025-10-29. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease [Phase 1, Phase 2]

See pricing